Hemcheck Sweden AB has signed an exclusive distribution agreement with PT Setia Guna Medika, a leading distributor of laboratory and medical equipment in Indonesia. The agreement is valid until the end of March 2023, concerning the Indonesian market. PT Setia Guna Medika has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR.

– PT Setia Guna Medika is a well-established distributor in Indonesia. We will perform product trials in the local market where they have a good network and customer relations. We look forward to starting the collaboration, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About PT Setia Guna Medika

PT Setia Guna Medika was founded in 2002 with its head office located in Jakarta. The company covers the whole Indonesian market and represents several international MedTech companies, from mainly from the US and Asia, with focus on laboratory medicine.

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.